125 related articles for article (PubMed ID: 12490317)
1. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma.
Fogel M; Mechtersheimer S; Huszar M; Smirnov A; Abu-Dahi A; Tilgen W; Reichrath J; Georg T; Altevogt P; Gutwein P
Cancer Lett; 2003 Jan; 189(2):237-47. PubMed ID: 12490317
[TBL] [Abstract][Full Text] [Related]
2. The adhesion molecule L1 (CD171) promotes melanoma progression.
Meier F; Busch S; Gast D; Göppert A; Altevogt P; Maczey E; Riedle S; Garbe C; Schittek B
Int J Cancer; 2006 Aug; 119(3):549-55. PubMed ID: 16506207
[TBL] [Abstract][Full Text] [Related]
3. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
5. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.
Bröcker EB; Magiera H; Herlyn M
J Invest Dermatol; 1991 May; 96(5):662-5. PubMed ID: 1850772
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
7. The distribution of cellular adhesion molecules in pigmented skin lesions.
van Duinen CM; van den Broek LJ; Vermeer BJ; Fleuren GJ; Bruijn JA
Cancer; 1994 Apr; 73(8):2131-9. PubMed ID: 7512443
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
Pluot M; Joundi A; Grosshans E
Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
[TBL] [Abstract][Full Text] [Related]
12. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
14. Multicellular origin of tenascin in skin tumors--an in situ hybridization study.
Tuominen H; Pöllänen R; Kallioinen M
J Cutan Pathol; 1997 Nov; 24(10):590-6. PubMed ID: 9449485
[TBL] [Abstract][Full Text] [Related]
15. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.
Gambichler T; Grothe S; Rotterdam S; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 Jun; 131(6):782-7. PubMed ID: 19461083
[TBL] [Abstract][Full Text] [Related]
16. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
17. Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice.
Danen EH; Jansen KF; Van Kraats AA; Cornelissen IM; Ruiter DJ; Van Muijen GN
Int J Cancer; 1995 May; 61(4):491-6. PubMed ID: 7538977
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Kuźbicki L; Sarnecka A; Chwirot BW
Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
[TBL] [Abstract][Full Text] [Related]
19. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
20. [The role of intermedial filament nestin in malignant melanoma progression].
Brychtová S; Fiurásková M; Brychta T; Hirnák J
Cesk Patol; 2005 Oct; 41(4):143-5. PubMed ID: 16382989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
